Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 108.80
ARWR's Cash to Debt is ranked higher than
52% of the 931 Companies
in the Global Biotechnology industry.

( Industry Median: 61.14 vs. ARWR: 108.80 )
Ranked among companies with meaningful Cash to Debt only.
ARWR' s Cash to Debt Range Over the Past 10 Years
Min: 0  Med: 33.21 Max: No Debt
Current: 108.8
Equity to Asset 0.83
ARWR's Equity to Asset is ranked higher than
71% of the 703 Companies
in the Global Biotechnology industry.

( Industry Median: 0.69 vs. ARWR: 0.83 )
Ranked among companies with meaningful Equity to Asset only.
ARWR' s Equity to Asset Range Over the Past 10 Years
Min: -39.56  Med: 0.76 Max: 0.95
Current: 0.83
-39.56
0.95
Interest Coverage N/A
ARWR's Interest Coverage is ranked lower than
51% of the 385 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. ARWR: N/A )
Ranked among companies with meaningful Interest Coverage only.
ARWR' s Interest Coverage Range Over the Past 10 Years
Min: N/A  Med: 9999.00 Max: 9999.99
Current: N/A
N/A
9999.99
F-Score: 3
Z-Score: 5.13
M-Score: -4.82
WACC vs ROIC
19.27%
-450.72%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -35233.59
ARWR's Operating margin (%) is ranked lower than
97% of the 728 Companies
in the Global Biotechnology industry.

( Industry Median: -65.33 vs. ARWR: -35233.59 )
Ranked among companies with meaningful Operating margin (%) only.
ARWR' s Operating margin (%) Range Over the Past 10 Years
Min: -30443.43  Med: -3442.52 Max: -520.49
Current: -35233.59
-30443.43
-520.49
Net-margin (%) -34619.92
ARWR's Net-margin (%) is ranked lower than
97% of the 728 Companies
in the Global Biotechnology industry.

( Industry Median: -63.93 vs. ARWR: -34619.92 )
Ranked among companies with meaningful Net-margin (%) only.
ARWR' s Net-margin (%) Range Over the Past 10 Years
Min: -33502.86  Med: -3192.77 Max: -513.78
Current: -34619.92
-33502.86
-513.78
ROE (%) -70.85
ARWR's ROE (%) is ranked lower than
74% of the 856 Companies
in the Global Biotechnology industry.

( Industry Median: -30.96 vs. ARWR: -70.85 )
Ranked among companies with meaningful ROE (%) only.
ARWR' s ROE (%) Range Over the Past 10 Years
Min: -225.02  Med: -94.07 Max: -28.66
Current: -70.85
-225.02
-28.66
ROA (%) -62.12
ARWR's ROA (%) is ranked lower than
78% of the 935 Companies
in the Global Biotechnology industry.

( Industry Median: -26.04 vs. ARWR: -62.12 )
Ranked among companies with meaningful ROA (%) only.
ARWR' s ROA (%) Range Over the Past 10 Years
Min: -154.73  Med: -76.38 Max: -22.16
Current: -62.12
-154.73
-22.16
ROC (Joel Greenblatt) (%) -2092.47
ARWR's ROC (Joel Greenblatt) (%) is ranked lower than
70% of the 899 Companies
in the Global Biotechnology industry.

( Industry Median: -363.62 vs. ARWR: -2092.47 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
ARWR' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -11843.37  Med: -1977.04 Max: -584.83
Current: -2092.47
-11843.37
-584.83
Revenue Growth (3Y)(%) -18.60
ARWR's Revenue Growth (3Y)(%) is ranked lower than
72% of the 478 Companies
in the Global Biotechnology industry.

( Industry Median: 4.50 vs. ARWR: -18.60 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
ARWR' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -52.00 Max: 64.8
Current: -18.6
0
64.8
EBITDA Growth (3Y)(%) -2.10
ARWR's EBITDA Growth (3Y)(%) is ranked lower than
51% of the 498 Companies
in the Global Biotechnology industry.

( Industry Median: -0.80 vs. ARWR: -2.10 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
ARWR' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -56.2  Med: -18.70 Max: 190.2
Current: -2.1
-56.2
190.2
EPS Growth (3Y)(%) -5.50
ARWR's EPS Growth (3Y)(%) is ranked lower than
53% of the 488 Companies
in the Global Biotechnology industry.

( Industry Median: -2.90 vs. ARWR: -5.50 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
ARWR' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -75.1  Med: -13.95 Max: 162.1
Current: -5.5
-75.1
162.1
» ARWR's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-05-11)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2014

ARWR Guru Trades in Q2 2014

George Soros Sold Out
» More
Q2 2015

ARWR Guru Trades in Q2 2015

Steven Cohen 22,200 sh (New)
» More
Q3 2015

ARWR Guru Trades in Q3 2015

Paul Tudor Jones 17,447 sh (New)
Steven Cohen Sold Out
» More
Q4 2015

ARWR Guru Trades in Q4 2015

Paul Tudor Jones 41,313 sh (+136.79%)
» More
» Details

Insider Trades

Latest Guru Trades with ARWR

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 3.62
ARWR's P/B is ranked lower than
54% of the 842 Companies
in the Global Biotechnology industry.

( Industry Median: 3.38 vs. ARWR: 3.62 )
Ranked among companies with meaningful P/B only.
ARWR' s P/B Range Over the Past 10 Years
Min: 1.65  Med: 4.63 Max: 71.58
Current: 3.62
1.65
71.58
P/S 1134.00
ARWR's P/S is ranked lower than
97% of the 671 Companies
in the Global Biotechnology industry.

( Industry Median: 10.84 vs. ARWR: 1134.00 )
Ranked among companies with meaningful P/S only.
ARWR' s P/S Range Over the Past 10 Years
Min: 4.04  Med: 161.59 Max: 4132.5
Current: 1134
4.04
4132.5
Current Ratio 6.67
ARWR's Current Ratio is ranked higher than
63% of the 905 Companies
in the Global Biotechnology industry.

( Industry Median: 4.73 vs. ARWR: 6.67 )
Ranked among companies with meaningful Current Ratio only.
ARWR' s Current Ratio Range Over the Past 10 Years
Min: 0.01  Med: 3.31 Max: 302.61
Current: 6.67
0.01
302.61
Quick Ratio 6.67
ARWR's Quick Ratio is ranked higher than
64% of the 905 Companies
in the Global Biotechnology industry.

( Industry Median: 4.54 vs. ARWR: 6.67 )
Ranked among companies with meaningful Quick Ratio only.
ARWR' s Quick Ratio Range Over the Past 10 Years
Min: 0.01  Med: 5.69 Max: 302.61
Current: 6.67
0.01
302.61

Valuation & Return

vs
industry
vs
history
Price/Net Cash 5.85
ARWR's Price/Net Cash is ranked lower than
52% of the 495 Companies
in the Global Biotechnology industry.

( Industry Median: 5.42 vs. ARWR: 5.85 )
Ranked among companies with meaningful Price/Net Cash only.
ARWR' s Price/Net Cash Range Over the Past 10 Years
Min: 0.05  Med: 7.11 Max: 103.64
Current: 5.85
0.05
103.64
Price/Net Current Asset Value 5.30
ARWR's Price/Net Current Asset Value is ranked lower than
52% of the 613 Companies
in the Global Biotechnology industry.

( Industry Median: 5.24 vs. ARWR: 5.30 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
ARWR' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 0.04  Med: 7.22 Max: 70.89
Current: 5.3
0.04
70.89
Price/Tangible Book 4.93
ARWR's Price/Tangible Book is ranked lower than
58% of the 776 Companies
in the Global Biotechnology industry.

( Industry Median: 4.11 vs. ARWR: 4.93 )
Ranked among companies with meaningful Price/Tangible Book only.
ARWR' s Price/Tangible Book Range Over the Past 10 Years
Min: 0.04  Med: 6.63 Max: 54.5
Current: 4.93
0.04
54.5
Price/Median PS Value 7.00
ARWR's Price/Median PS Value is ranked lower than
95% of the 574 Companies
in the Global Biotechnology industry.

( Industry Median: 0.95 vs. ARWR: 7.00 )
Ranked among companies with meaningful Price/Median PS Value only.
ARWR' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.03  Med: 0.61 Max: 23.08
Current: 7
0.03
23.08
Earnings Yield (Greenblatt) (%) -34.53
ARWR's Earnings Yield (Greenblatt) (%) is ranked lower than
81% of the 897 Companies
in the Global Biotechnology industry.

( Industry Median: -7.90 vs. ARWR: -34.53 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
ARWR' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -105.61  Med: 0.00 Max: 0
Current: -34.53
-105.61
0

More Statistics

Revenue(Mil) $0
EPS $ -1.52
Beta2.33
Short Percentage of Float19.09%
52-Week Range $3.07 - 9.36
Shares Outstanding(Mil)59.63

Analyst Estimate

Sep16 Sep17
Revenue(Mil) 0 0
EPS($) -1.43 -1.38
EPS without NRI($) -1.43 -1.38

Business Description

Industry: Biotechnology » Biotechnology
Compare:NAS:RPTP, NAS:ARNA, NAS:BPMC, NAS:XBIT, XKRX:031390, XKRX:049960 » details
Traded in other countries:HDP1.Germany,
Arrowhead Research Corp was originally incorporated in South Dakota in the year 1989, and was reincorporated in Delaware in 2000. The Company is a biopharmaceutical company developing targeted RNAi therapeutics. The Company is leveraging its proprietary drug delivery technologies to develop drugs based on the RNA interference mechanism that efficiently silences disease-causing genes. Its pipeline includes clinical programs in chronic hepatitis B virus and partner-based programs in obesity and oncology. Its products include ARC-520, Adipotide. The Company controls 306 patents. The Company and its products are regulated by FDA under the Federal Food, Drug and Cosmetic Act (the FDCA), and other laws within the Public Health Service Act.
» More Articles for ARWR

Headlines

Articles On GuruFocus.com
Arrowhead Research Making Headway In The RNAi Therapy Platform Mar 09 2015 
Weekly CEO Buys Highlight: NRP, OPK, GAM, KEY, ARWR Oct 20 2014 
Arrowhead Research Corp. Reports Operating Results (10-Q) Feb 10 2011 
Weekly CFO Buys Highlight: JAZZ, VRTB, ASTM, ARWR, CGX Sep 04 2010 
Arrowhead Research Corp. Reports Operating Results (10-Q) May 13 2010 
Arrowhead Research Corp. Reports Operating Results (10-Q) Feb 11 2010 
Arrowhead Research Corp. Reports Operating Results (10-K) Dec 22 2009 
Arrowhead Research Corp. Reports Operating Results (10-Q) Aug 10 2009 
Arrowhead Research Corp. Reports Operating Results (10-Q) May 15 2009 
Arrowhead Research Corp. Reports Operating Results (10-Q) Feb 09 2009 

More From Other Websites
Arrowhead Pharmaceuticals to Webcast Fiscal 2016 Second Quarter Results May 03 2016
Arrowhead Pharmaceuticals to Webcast Fiscal 2016 Second Quarter Results May 03 2016
Arrowhead Pharmaceuticals to Present at Upcoming May Conferences Apr 29 2016
Arrowhead Pharmaceuticals to Present at Upcoming May Conferences Apr 29 2016
Arrowhead Pharmaceuticals Files for Regulatory Clearance to Begin Phase 1/2 Study of ARC-521 Apr 28 2016
Arrowhead Pharmaceuticals Files for Regulatory Clearance to Begin Phase 1/2 Study of ARC-521 Apr 28 2016
Arrowhead Pharmaceuticals Files for Regulatory Clearance to Begin Phase 1/2 Study of ARC-521 Apr 28 2016
Arrowhead Pharmaceuticals Presents Preclinical Data on Renal Cell Carcinoma Program at AACR 2016 Apr 18 2016
Arrowhead Pharmaceuticals Presents Preclinical Data on Renal Cell Carcinoma Program at AACR 2016 Apr 18 2016
Time For Another Biotech Rally Apr 18 2016
4 Hot Trending Small Cap Stocks That You Haven't Heard About Apr 14 2016
Arrowhead Pharmaceuticals Presents Promising ARC-520 Hepatitis B Data at The International Liver... Apr 14 2016
Arrowhead Pharma (ARWR) Stock Spikes on Promising Hepatitis B Data Apr 13 2016
Why JPMorgan (JPM), Facebook (FB), and Fitbit (FIT) Are Among Today’s Trending Stocks Apr 13 2016
Arrowhead Pharmaceuticals Presents Promising ARC-520 Hepatitis B Data at The International Liver... Apr 13 2016
Trending Now: ARWR Apr 12 2016
ARROWHEAD PHARMACEUTICALS, INC. Financials Apr 12 2016
ARROWHEAD RESEARCH CORP Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in... Apr 06 2016
Arrowhead Research Changes Name to Arrowhead Pharmaceuticals Apr 06 2016
Arrowhead Research Changes Name to Arrowhead Pharmaceuticals Apr 06 2016
Arrowhead to Present at Upcoming April Conferences Mar 30 2016
Arrowhead to Present at Upcoming April Conferences Mar 30 2016
ARROWHEAD RESEARCH CORP Files SEC form 8-K, Submission of Matters to a Vote of Security Holders Mar 10 2016
Arrowhead Presents Promising New Preclinical Data on ARC-F12 at AAAAI 2016 Mar 07 2016
Arrowhead to Present at Upcoming March Conferences Mar 01 2016
Arrowhead to Present at Upcoming February Conferences Feb 16 2016
Arrowhead Research Corp. Earnings Analysis: Q1, 2016 By the Numbers Feb 16 2016
Arrowhead Research reports 1Q loss Feb 09 2016
Arrowhead's ARC-AAT Granted EMA Orphan Drug Designation Jan 19 2016
Arrowhead Research reports 4Q loss Dec 14 2015
Arrowhead Reports Fiscal 2015 Year End Results Dec 14 2015
Arrowhead to Webcast Fiscal 2015 Year End Results Dec 07 2015
Arrowhead's ARC-520 Leads to Consistent Immune Reactivation in Chimpanzees with Chronic Hepatitis B... Dec 07 2015
Arrowhead Late-Breaking Clinical Data Shows that ARC-520 Can Produce Deep and Durable Reductions of... Nov 16 2015
Arrowhead Presents Data Showing Robust Sustained Anti-viral Effects with ARC-520 in Hepatitis B... Nov 15 2015
Arrowhead to Present at Upcoming Conferences Nov 11 2015
Arrowhead Late-Breaker Abstract Accepted for Presentation at the AASLD Liver Meeting 2015 Oct 20 2015
Arrowhead Presents Overview of Its Broad RNAi Delivery Platform and Introduces New Subcutaneously... Oct 14 2015
Arrowhead Reports Peak Reduction in HBsAg of Up to 99% (1.9 log) After a Single Dose with Hepatitis... Sep 24 2015
Arrowhead to Webcast Analyst Day Presentation on Hepatitis B Candidate ARC-520 Sep 23 2015
Arrowhead Nominates ARC-HIF2 As First RNAi Therapeutic Candidate Using Extrahepatic DPC™ Delivery... Sep 23 2015
Arrowhead Research reports 3Q loss Aug 04 2015
Arrowhead Research reports 2Q loss May 11 2015
Arrowhead Research reports 1Q loss Feb 09 2015
Arrowhead Research misses 4Q profit forecasts Nov 25 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK